X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is being evaluated for the treatment of patients with locally advanced or metastatic biliary tract cancer.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody drug candidate, which is currently being evaluated in combination with tremelimumab for the treatment of limited-stage small cell lung cancer.
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
Imfinzi (durvalumab), a PD-L1 inhibitor plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib), a PARP inhibitor, demonstrated an improvement in patients with mismatch repair proficient advanced endometrial cancer compared to chemotherapy alone.
Lead Product(s): Durvalumab,Olaparib
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is under phase 1/2 clinical development in combination with Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is being evaluated under phase 1/2 clinical trials in combination with anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of late-stage pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Transarterial Chemoembolization (TACE) in combination with Imfinzi (Durvalumab) and Bevacizumab is being evaluated in phase 3 clinical trials for the treatment of Hepatocellular Carcinoma.
Lead Product(s): Durvalumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is under phase 1/2 clinical development in combination with Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Imfinzi (durvalumab) a PD-L1 inhibitor in combination with Dato-DXd (datopotamab deruxtecan) a TOP1 inhibitor is being evaluated in phase 3 clinical trials for the treatment of patients with early-stage triple negative and HR low, HER2 low or negative breast cancers.
Lead Product(s): Datopotamab Deruxtecan,Durvalumab
Therapeutic Area: Oncology Product Name: Dato-DXd
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is being evaluated in phase 3 clinical trials for the treatment of unresectable, Stage III non-small cell lung cancer.
Lead Product(s): Durvalumab,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is approved for the treatment of patients with locally advanced or metastatic biliary tract cancer in China.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Imfinzi (durvalumab) is a human mAb that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
Imfinzi (durvalumab) a PD-L1 inhibitor in combination with Dato-DXd (datopotamab deruxtecan) a TOP1 inhibitor is being evaluated in phase 1/2 clinical trials for the treatment of patients with metastatic triple-negative breast cancer.
Lead Product(s): Datopotamab Deruxtecan,Durvalumab
Therapeutic Area: Oncology Product Name: Dato-DXd
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2023
Details:
Dato-DXd (datopotamab deruxtecan) in combination with Imfinzi (durvalumab) is being evaluated in phase 1/2 clinical trials for the treatment of advanced or metastatic triple negative breast cancer.
Lead Product(s): Datopotamab Deruxtecan,Durvalumab
Therapeutic Area: Oncology Product Name: Dato-DXd
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2023
Details:
Imfinzi (durvalumab) a PD-L1 inhibitor in combination with Lynparza (olaparib) is a first-in-class PARP inhibitor is being evaluated in phase 3 clinical trials for the treatment of advanced or recurrent endometrial cancer.
Lead Product(s): Durvalumab,Olaparib
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody drug candidate, which is currently being evaluated in combination with fluorouracil & leucovorin for the treatment of resectable gastric and gastroesophageal junction cancer.
Lead Product(s): Durvalumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
The collaboration aims to evaluate BioCity's BC3402, a mAb targeting the T cell immunoglobulin and mucin domain-containing protein 3, in combination with AstraZeneca's anti-PD-L1 mAb IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma in China.
Lead Product(s): BC3402,Durvalumab
Therapeutic Area: Oncology Product Name: BC3402
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
Dato-DXd (datopotamab deruxtecan) in combination with Imfinzi (durvalumab) is being evaluated in phase 1 clinical trials for the treatment of advanced non-small cell lung cancer.
Lead Product(s): Datopotamab Deruxtecan,Durvalumab
Therapeutic Area: Oncology Product Name: Dato-DXd
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and evaluating Phase 1b/2 Study Combination with Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC).
Lead Product(s): IPH5201,Durvalumab,Carboplatin
Therapeutic Area: Oncology Product Name: IPH5201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Imfinzi (durvalumab) is a human mAb that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Olaparib
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Imfinzi (durvalumab) is a human mAb that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Carboplatin,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2023
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.
Lead Product(s): Olaparib,Durvalumab
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
Imfinzi (durvalumab) is a human mAb that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Carboplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
A combination of human mAb, imfinzi (durvalumab) and imjudo (tremelimumab) where one binds and inhibts PD-L1 protein, countering the tumour's immune-evading tactics and other that targets the activity of CTLA-4, activating T-cell, is approved in EU for treating HCC and NSCLC.
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of PD-L1 with PD-1 and CD80 to release the inhibition of immune responses, without inducing antibody-dependent cell-mediated cytotoxicity.
Lead Product(s): Durvalumab
Therapeutic Area: Oncology Product Name: Durvalumab-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
The research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
There was an improvement in OS with Imfinzi monotherapy, which was clinically meaningful in the subset of patients with PD-L1 tumour expression greater than 50%, a secondary endpoint. The trial was conducted primarily in Asia.
Lead Product(s): Durvalumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Datopotamab deruxtecan (Dato-DXd) is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative.
Lead Product(s): Datopotamab Deruxtecan,Durvalumab
Therapeutic Area: Oncology Product Name: Dato-DXd
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Tremelimumab,Carboplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Imjudo (tremelimumab) is a human monoclonal antibody that targets activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo blocks the activity of CTLA-4, contributing to T-cell activation, priming the immune response to cancer and fostering cancer cell death.
Lead Product(s): Tremelimumab,Durvalumab
Therapeutic Area: Oncology Product Name: Imjudo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment.
Lead Product(s): VCN-01,Durvalumab
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Updated results from TOPAZ-1 Phase III trial showed IMFINZI® (durvalumab), in combination with standard-of-care chemotherapy demonstrated a clinically meaningful and durable overall survival (OS) benefit as a treatment for patients with advanced biliary tract cancer (BTC).
Lead Product(s): Durvalumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Results showed MEDI4736 (durvalumab) maintenance therapy did not prolong PFS or OS compared to active surveillance in HER2-negative patients unselected for PD-L1 status.
Lead Product(s): Durvalumab
Therapeutic Area: Oncology Product Name: MEDI4736
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Royal Marsden NHS Foundation Trust
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Results for Imfinzi (durvalumab) plus chemotherapy (gemcitabine plus cisplatin) showed enhanced clinical efficacy after an additional 6.5 months of follow-up, demonstrating a 24% reduction in the risk of death versus chemotherapy alone.
Lead Product(s): Durvalumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Exploratory analysis from POSEIDON Phase III trial also showed trends for overall survival benefit with a limited course of tremelimumab added to Imfinzi (durvalumab) and chemotherapy in subgroups with high unmet need.
Lead Product(s): Durvalumab,Tremelimumab,Pemetrexed
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Details:
Approval by FDA was based on results from TOPAZ-1 Phase III trial. In an interim analysis of TOPAZ-1, Imfinzi (durvalumab) plus chemotherapy reduced risk of death by 20% versus chemotherapy alone (hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.66-0.97; p=0.021).
Lead Product(s): Durvalumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment.
Lead Product(s): VCN-01,Durvalumab
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
Immunocore expects to use the proceeds from the PIPE to fund its oncology and infectious disease clinical pipeline including the continued clinical development of Kimmtrak (tebentafusp) in advanced cutaneous melanoma and ImmTAC clinical candidates targeting MAGE-A4 and PRAME.
Lead Product(s): Tebentafusp,Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Kimmtrak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 18, 2022
Details:
HIMALAYA Phase III trial subgroup analysis showed that IMFINZI (durvalumab) plus tremelimumab improved overall survival vs.sorafenib in patients with unresectable liver cancer regardless of baseline liver functional reserve.
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2022
Details:
Positive results from AEGEAN Phase III trial showed treatment with Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery demonstrated significant and meaningful improvement in pCR compared to neoadjuvant chemotherapy alone for patients with nSCLC.
Lead Product(s): Durvalumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway. CD39 is an extracellular enzyme that is expressed in the tumor microenvironment, on both tumor infiltrating cells and stromal cells in several cancer types.
Lead Product(s): IPH5201,Oleclumab,Durvalumab
Therapeutic Area: Oncology Product Name: IPH5201
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $75.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration June 03, 2022
Details:
KIMMTRAK (Tebentafusp), is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
Lead Product(s): Tebentafusp,Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Kimmtrak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
The data showed Imfinzi (durvalumab) plus chemotherapy (gemcitabine plus cisplatin) reduced the risk of death by 20% versus chemotherapy alone (based on a hazard ratio [HR] of 0.80; 95% confidence interval [CI], 0.66-0.97; 2-sided p=0.021).
Lead Product(s): Durvalumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.
Lead Product(s): Monalizumab,Durvalumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $450.0 million Upfront Cash: $250.0 million
Deal Type: Agreement April 29, 2022
Details:
STRIDE regimen of a single priming dose of tremelimumab added to Imfinzi is the first dual immune checkpoint blockade regimen to improve overall survival in a Phase III trial in this setting.
Lead Product(s): Tremelimumab,Durvalumab
Therapeutic Area: Oncology Product Name: CP-675
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
CALLA Phase III trial for Imfinzi (durvalumab) given concurrently with chemoradiotherapy did not achieve statistical significance for primary endpoint of improving progression-free survival versus CRT alone in treatment of patients with locally advanced cervical cancer.
Lead Product(s): Durvalumab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
